Intenи›ii

This clinical-stage biotech company recently reported financial and clinical updates for the second quarter of 2025. They are currently testing INT230-6 , a drug for direct tumor injection, with their Q2 2025 Financial Report showing a net loss of $2.5 million.

If the query refers to a specific company with a similar name: IntenИ›ii